Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). People with SCID lack virtually all immune protection from bacteria, viruses, and fungi. They are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by "opportunistic" organisms that ordinarily do not cause illness in people with a normal immune system.
Adenosine deaminase deficiency is caused by mutations in the ADA gene. This gene provides instructions for producing the enzyme adenosine deaminase. This enzyme is found throughout the body but is most active in specialized white blood cells called lymphocytes. These cells protect the body against potentially harmful invaders, such as bacteria and viruses, by making immune proteins called antibodies or by directly attacking infected cells. Lymphocytes are produced in specialized lymphoid tissues including the thymus, which is a gland located behind the breastbone, and lymph nodes, which are found throughout the body. Lymphocytes in the blood and in lymphoid tissues make up the immune system.
Adenosine deaminase deficiency is very rare and is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide. This disorder is responsible for approximately 15 percent of SCID cases.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Donald Kohn is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Los Angeles, California. Kohn is rated as an Elite expert by MediFind in the treatment of Adenosine Deaminase Deficiency. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, X-Linked Severe Combined Immunodeficiency, Sickle Cell Disease, and Bone Marrow Transplant. Kohn is currently accepting new patients.
Eyal Grunebaum practices in Toronto, Canada. Grunebaum is rated as an Elite expert by MediFind in the treatment of Adenosine Deaminase Deficiency. He is also highly rated in 9 other conditions, according to our data. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, Purine Nucleoside Phosphorylase Deficiency, ZAP70-Related Severe Combined Immunodeficiency, and Bone Marrow Transplant.
Robert Sokolic is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Sokolic has been practicing medicine for over 27 years and is rated as a Distinguished expert by MediFind in the treatment of Adenosine Deaminase Deficiency. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, Chronic Lymphocytic Leukemia (CLL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Transplant. Sokolic is currently accepting new patients.
Summary: The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
Summary: This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as...
Published Date: July 01, 2013Published By: National Institutes of Health